On Monday, KalVista Pharmaceuticals Inc (NASDAQ: KALV) opened higher 9.49% from the last session, before settling in for the closing price of $11.80. Price fluctuations for KALV have ranged from $7.30 to $15.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -3.28% at the time writing. With a float of $38.50 million, this company’s outstanding shares have now reached $49.49 million.
The extent of productivity of a business whose workforce counts for 150 workers is very important to gauge. In terms of profitability, gross margin is 63.27%, operating margin of -15043.2%, and the pretax margin is -14230.76%.
KalVista Pharmaceuticals Inc (KALV) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of KalVista Pharmaceuticals Inc is 22.56%, while institutional ownership is 88.36%. The most recent insider transaction that took place on May 23 ’25, was worth 24,272. In this transaction CHIEF MEDICAL OFFICER of this company sold 2,146 shares at a rate of $11.31, taking the stock ownership to the 113,026 shares. Before that another transaction happened on May 23 ’25, when Company’s CHIEF DEVELOPMENT OFFICER sold 1,926 for $11.31, making the entire transaction worth $21,782. This insider now owns 98,189 shares in total.
KalVista Pharmaceuticals Inc (KALV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.36% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Check out the current performance indicators for KalVista Pharmaceuticals Inc (KALV). In the past quarter, the stock posted a quick ratio of 10.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -2.98 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
The latest stats from [KalVista Pharmaceuticals Inc, KALV] show that its last 5-days average volume of 0.63 million was superior to 0.51 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 69.18%. Additionally, its Average True Range was 0.69.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 83.88%, which indicates a significant increase from 80.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.84% in the past 14 days, which was higher than the 55.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.00, while its 200-day Moving Average is $10.89. Now, the first resistance to watch is $13.52. This is followed by the second major resistance level at $14.13. The third major resistance level sits at $14.88. If the price goes on to break the first support level at $12.16, it is likely to go to the next support level at $11.41. The third support level lies at $10.80 if the price breaches the second support level.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
There are currently 49,716K shares outstanding in the company with a market cap of 642.32 million. Presently, the company’s annual sales total 0 K according to its annual income of -126,640 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -48,510 K.
